After three decades climbing the ranks at medical device giants like Boston Scientific and Baxter, a seasoned executive faced a choice that would have given most leaders pause: take the safe route to a public company CEO role, or dive headfirst into the uncertain world of AI in healthcare. The pull toward AI proved irresistible.
AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty
Related Articles
Mayo Clinic launches remote diagnostics platform, forms 2 new companies to support it
Healthcare IT News: Anumana will develop and market algorithms for early detection of disease. Lucem Health can collect device data and feed it into clinical workflows. Both spin-offs aim to…April 13, 2021
Pfizer and Anumana boost detection of cardiovascular disease
Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.December 16, 2022
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.October 02, 2023
Philips Launches ECG-AI Marketplace to Enhance Early Cardiac Diagnosis
Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystemJuly 17, 2025